Literature DB >> 16793677

Formation of platelet-leukocyte conjugates in whole blood.

H Redlich1, J Vickers, W Lösche, S Heptinstall, B Kehrel, P Spangenberg.   

Abstract

The purpose of this investigation was to obtain information on platelet-leukocyte conjugate formation in whole blood and on factors that affect it. We also measured platelet and leukocyte activation by quantitating the expression of CD62P and CD11b. In both cases a flow cytometric approach was used. The results show that platelet-monocyte and platelet-polymorphonuclear leukocyte (PMNL) conjugate formation is enhanced by simply stirring blood, with optimum conjugate formation occurring after 10 min. In the case of monocytes,conjugate formation was enhanced by adenosine diphosphate (ADP). Both monocyte and PMNL conjugate formation was enhanced by phorbol myristate acetate (PMA), but L-formyl methionyl lysyl proline (FMLP) was either without effect (monocytes) or inhibitory (PMNL). EDTA also inhibited conjugate formation (implying involvement of divalent cations), as did dextran sulphate (implying involvement of P-selectin = CD62P). Interestingly GR144053F, which acts at GpIIb-IIIa on platelets to interfere with fibrinogen binding, and also glycyl prolyl arginyl proline (GPRP), a peptide that interferes with the interaction between CD11c on leukocytes and fibrinogen, did not inhibit platelet-monocyte conjugate formation, but did inhibit the platelet-PMNL interaction; this indicates that GpIIb-IIIa on platelets and CD11c on leukocytes and fibrinogen are involved in mediating the interaction between platelets and PMNL but not platelets and monocytes. Surprisingly arginyl-glycyl aspartyl serine (RGDS) inhibited the formation of both types of conjugate but this may be because it also inhibited both platelet and leukocyte activation as measured by CD62P and CD11b exposure and/or interferes with the binding of adhesion molecules other than fibrinogen. The results show that a flow cytometric procedure can be effective in obtaining rapid information on platelet-leukocyte conjugate formation in whole blood and on factors that are involved in its regulation. It is suggested that the technique may be applicable to the study of platelet-leukocyte conjugate formation in whole blood in disease, and also to study the effects of drugs interfering with conjugate formation.

Entities:  

Year:  1997        PMID: 16793677     DOI: 10.1080/09537109777113

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  4 in total

1.  HES 130/0.4 impairs haemostasis and stimulates pro-inflammatory blood platelet function.

Authors:  Maik Sossdorf; Sascha Marx; Barbara Schaarschmidt; Gordon P Otto; Ralf A Claus; Konrad Reinhart; Christiane S Hartog; Wolfgang Lösche
Journal:  Crit Care       Date:  2009-12-22       Impact factor: 9.097

2.  Fibrin(ogen) Is Constitutively Expressed by Differentiated Intestinal Epithelial Cells and Mediates Wound Healing.

Authors:  Amira Seltana; Gabriel Cloutier; Vilcy Reyes Nicolas; Taoufik Khalfaoui; Inga C Teller; Nathalie Perreault; Jean-François Beaulieu
Journal:  Front Immunol       Date:  2022-06-22       Impact factor: 8.786

3.  Analysis of platelet-activating factors in severe sepsis by flow cytometry and its correlation with clinical sepsis scoring system: A pilot study.

Authors:  V Manu; Barun K Chakrabarty; Shivinder Singh
Journal:  Med J Armed Forces India       Date:  2018-10-10

4.  Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients.

Authors:  Sascha Marx; Maximilian Splittstöhser; Frederik Kinnen; Eileen Moritz; Christy Joseph; Sebastian Paul; Heiko Paland; Carolin Seifert; Madlen Marx; Andreas Böhm; Edzard Schwedhelm; Kerstin Holzer; Stephan Singer; Christoph A Ritter; Sandra Bien-Möller; Henry W S Schroeder; Bernhard H Rauch
Journal:  Oncotarget       Date:  2018-05-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.